InMed Pharmaceuticals, Inc. (IMLFF) Adds to Its Drug Development Pipeline

A pre-clinical stage biopharmaceutical company, InMed Pharmaceuticals, Inc. (OTCQB: IMLFF) has revealed two additions to its drug development pipeline. An expedited drug development timeline is now in place for INM-750 for epidermolysis bullosa (EB), with a potential market of about $1 billion. The disease is characterized by fragile skin in children. The company has also announced the development of INM-085 for glaucoma, which represents a potential global market of over $5 billion.

Resulting in a defect in the connective tissue between the dermis and epidermis, most often caused by a lack of keratins, EB currently has no medication-based treatments. Multiple cannabinoids are the active ingredients of INM-750, which is now under development as a topical drug. These were selected to manage keratin levels in people with EB, in which fragile skin can blister and tear easily with the slightest…

Read More >>

About NetworkNewsWire

NetworkNewsWire (NNW) provides news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s